NEW YORK, May 1 – Protein structure determination company Signature BioScience said Tuesday it had appointed David Spellmeyer chief scientific officer and vice president of drug discovery.

Spellmeyer will be in charge of developing Signature BioScience’s new drug discovery efforts and validating the company’s technology.

Previously Spellmeyer was executive director at DuPont Pharmaceuticals Research Laboratories, where he oversaw the computational chemistry aspects of drug discovery and information technologies.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.